The New York-based pharmaceutical giant, which has its world research-and-development headquarters in New London, Conn., said it has entered into licensing agreements with two Indian pharmaceutical companies that deal in generics.
The deals with Aurobindo Pharma Ltd. and Claris Lifesciences Ltd. will bring more than 100 generic medications into the Pfizer fold throughout North America, and slightly fewer in Asia, Latin America, Africa and the Middle East.--Nina Lentini